International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 4 , Pages 969-974 , 15 November 2010

ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non–Small-Cell Lung Cancer: Expert Panel on Radiation Oncology–Lung

  • Ramesh S. Gopal, M.D., Ph.D.

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests to: Ramesh Gopal, M.D., Ph.D., University of Texas M.D. Anderson Cancer Center, 1605 Adelita Dr., NE, Albuquerque, NM 87112-4909. Tel: (505) 291-2506; Fax: (505) 291-2622
    • ,
  • Sarita Dubey, M.D.

      Affiliations

    • University of California, San Francisco, San Francisco, CA and American Society of Clinical Oncology
    • ,
  • Kenneth E. Rosenzweig, M.D.

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Joe Yujiao Chang, M.D., Ph.D.

      Affiliations

    • M.D. Anderson Cancer Center, Houston, TX
    • ,
  • Roy Decker, M.D.

      Affiliations

    • Yale University School of Medicine, New Haven, CT
    • ,
  • Richard M. Gewanter, M.D.

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY
    • ,
  • Feng-Ming Kong, M.D., Ph.D., M.P.H.

      Affiliations

    • Veterans Affairs Health Center, Ann Arbor, MI
    • ,
  • Brian E. Lally, M.D.

      Affiliations

    • University of Miami, Miami, FL
    • ,
  • Corey J. Langer, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA and American Society of Clinical Oncology
    • ,
  • Hoon Ku Lee, M.D.

      Affiliations

    • Regional Imaging and Therapeutic Radiology Services, PC, Staten Island, NY
    • ,
  • Benjamin Movsas, M.D.

      Affiliations

    • Henry Ford Health System, Detroit, MI

Received 29 June 2010 ,Accepted 1 July 2010.

References 

  1. Ginsberg RJ. Multimodality therapy for stage IIIA (N2) lung cancer: An overview. Chest. 1993;103(Suppl.):356S–359S
  2. van Klaveren RJ, Festen J, Otten HJ, et al. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg. 1993;56:300–304
  3. Watanabe Y, Shimizu J, Oda M, et al. Results of surgical treatment in patients with stage IIIA non–small-cell lung cancer. Thorac Cardiovasc Surg. 1991;39:44–49
  4. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986;315:1377–1381
  5. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non–small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352:257–263
  6. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non–small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2006;24:2998–3006
  7. Douillard JY, Rosell R, Delena M, et al. Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non–small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association [Abstract]. J Clin Oncol. 2005;23(abstr 7013):16s
  8. Chemotherapy in non–small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909
  9. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer. J Natl Cancer Inst. 2003;95:1453–1461
  10. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer. N Engl J Med. 2004;350:351–360
  11. Le Chevalier T, Dunant A, Arriagada R, et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) [Abstract]. J Clin Oncol. 2008;26:suppl; abstr 7507
  12. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  13. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non–small-cell lung cancer. J Clin Oncol. 2002;20:247–253
  14. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non–small-cell lung cancer. N Engl J Med. 1994;330:153–158
  15. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  16. Pisters K, Vallieres E, Bunn PA, et al. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18s):7520
  17. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. 2007;369:1929–1937
  18. Scagliotti GV, Pastorino U, Vansteenkiste J, et al. A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.T. [Abstract]. J Clin Oncol. 2008;26:suppl; abstr 7507
  19. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23
  20. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611–621
  21. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  22. Thomas M, Macha N, Ukena D, et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). Proc Am Soc Clin Oncol. 2003;22(abstr 2497):621
  23. van Meerbeeck JP, Kramer G, Van Schil PE, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol (Meeting Abstracts). 2005;23:LBA7015
  24. Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from Intergroup trial 0139 (RTOG 93-09) [Abstract]. Proc Am Soc Clin Oncol. 2003;22(abstr 2497):621

 This article summarizes the American College of Radiology Appropriateness Criteria on Induction and Adjuvant Therapy for N2 Non-Small-Cell Lung Cancer, excerpts of which are reprinted here with permission. Practitioners are encouraged to refer to the complete version at www.acr.org/ac

 Conflict of interest: none.

PII: S0360-3016(10)00961-2

doi: 10.1016/j.ijrobp.2010.07.028

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 4 , Pages 969-974 , 15 November 2010

Article Tools